Related Experiment Video
Updated: Dec 27, 2025
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental
Ariel L Hernandez1, Christian D Young1, Li Bian1
1Department of Pathology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Purpose:
SMAD4 loss causes genomic instability and the initiation/progression of head and neck squamous cell carcinoma (HNSCC). Here, we study whether SMAD4 loss sensitizes HNSCCs to olaparib (PARP inhibitor) in combination with radiotherapy (RT).
Experimental Design:
We analyzed HNSCC The Cancer Genome Atlas data for SMAD4 expression in association with FANC/BRCA family gene expression. Human HNSCC cell lines were screened for sensitivity to olaparib. Isogenic HNSCC cell lines were generated to restore or reduce SMAD4 expression and treated with olaparib, radiation, or the combination. HNSCC pretreatment specimens from a phase I trial investigating olaparib were analyzed.
Results:
SMAD4 levels correlated with levels of FANC/BRCA genes in HNSCC. HNSCC cell lines with SMAD4 homozygous deletion were sensitive to olaparib. In vivo, olaparib or RT monotherapy reduced tumor volumes in SMAD4-mutant but not SMAD4-positive tumors. Olaparib with RT dual therapy sustained tumor volume reduction in SMAD4-deficient (mutant or knockdown) xenografts, which exhibited increased DNA damage and cell death compared with vehicle-treated tumors. In vitro, olaparib alone or in combination with radiation caused lower clonogenic survival, more DNA damage-associated cell death, and less proliferation in SMAD4-deficient cells than in SMAD4-positive (endogenous SMAD4 or transduced SMAD4) cells. Applicable to clinic, 5 out of 6 SMAD4-negative HNSCCs and 4 out of 8 SMAD4-positive HNSCCs responded to a standard treatment plus olaparib in a phase I clinical trial, and SMAD4 protein levels inversely correlated with DNA damage.
Conclusions:
SMAD4 levels are causal in determining sensitivity to PARP inhibition in combination with RT in HNSCCs.
Insights
Loss of SMAD4 in head and neck squamous cell carcinoma (HNSCC) sensitizes tumors to olaparib (a PARP inhibitor) combined with radiotherapy. This combination therapy shows promise for treating SMAD4-deficient HNSCC.
Area of Science:
- Oncology
- Genetics
- Cancer Biology
Background:
- SMAD4 loss is a driver of genomic instability and progression in head and neck squamous cell carcinoma (HNSCC).
- Understanding genetic alterations that predict treatment response is crucial for optimizing HNSCC therapy.
Purpose of the Study:
- To investigate if SMAD4 loss sensitizes HNSCC to combination therapy with olaparib (a PARP inhibitor) and radiotherapy (RT).
- To explore the correlation between SMAD4 expression and sensitivity to olaparib and RT in HNSCC.
Main Methods:
- Analysis of The Cancer Genome Atlas (TCGA) data for SMAD4 and FANC/BRCA gene expression in HNSCC.
- Screening of HNSCC cell lines for olaparib sensitivity.
- Generation of isogenic HNSCC cell lines with altered SMAD4 expression for in vitro and in vivo studies with olaparib and RT.
- Analysis of HNSCC specimens from a Phase I clinical trial of olaparib.
Main Results:
- SMAD4 levels correlated with FANC/BRCA gene expression in HNSCC.
- HNSCC cell lines with SMAD4 deletion were sensitive to olaparib.
- Olaparib plus RT combination therapy reduced tumor volumes and increased DNA damage and cell death in SMAD4-deficient xenografts.
- SMAD4-deficient cells showed reduced clonogenic survival and proliferation, and increased DNA damage-associated cell death in vitro.
- Clinical trial data indicated a higher response rate to olaparib plus standard treatment in SMAD4-negative HNSCC.
Conclusions:
- SMAD4 status is a critical determinant of sensitivity to olaparib in combination with radiotherapy in HNSCC.
- Targeting PARP with olaparib in conjunction with RT represents a potential therapeutic strategy for SMAD4-deficient HNSCC.
